INTERCELL ENTERS INTO STRATEGIC PARTNERSHIP WITH WYETH FOR THE USE OF ITS IC31 ADJUVANT

Intercell AG announced that it has closed a worldwide non-exclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31 in various selected infectious disease vaccine programs. Under the agreement, Intercell may be entitled to receive up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/6356/118/)